Acción MVIR B MEDIVIR AB
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Medivir AB

Acciones

MVIR B

SE0020181014

Mercado cerrado - Nasdaq Stockholm
Otros sitios de cotización
 12:59:59 08/05/2024 		Varia. Cinco días. Varia. 1 de enero.
3,03 SEK +1,00 % Gráfico intradía de Medivir AB -3,81 % +6,32 %
07/05 Medivir Aktiebolag (publ) aprueba los nombramientos del consejo de administración CI
30/04 Transcript : Medivir AB, Q1 2024 Earnings Call, Apr 30, 2024

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Resolutions at the Annual General Meeting in Medivir on 7 May 2024
Medivir Aktiebolag Approves Board Appointments
BioStock: Double thumbs up for Medivir from the FDA
MEDIVIR AB - INTERIM REPORT JANUARY - MARCH 2024
Medivir AB Reports Earnings Results for the First Quarter Ended March 31, 2024
Medivir brings the Q1 webcast forward to 10 a.m. on April 30
Medivir to present data for the combination of fostrox + Lenvima in HCC at ESMO GI
Medivir AB Provides Update from Positive Type C Meeting with the FDA; Preparations for Enhanced Phase 2b in HCC with Fostrox + Lenvima
BioStock: Medivir optimizes study design after meeting FDA
Medivir Gets Two US FDA Designations for MIV-711
Medivir : FDA grants Medivir´s MIV-711 Rare Pediatric Disease Designation and Orphan Drug Designation for the treatment of Legg-Calvé-Perthes Disease
FDA grants Medivir's MIV-711 Rare Pediatric Disease Designation and Orphan Drug Designation for the treatment of Legg-Calvé-Perthes Disease
FDA Grants Medivir AB´S MIV-711 Rare Pediatric Disease Designation and Orphan Drug Designation for the Treatment of Legg-Calvé-Perthes Disease
Medivir provides update from supportive Type C meeting with the FDA; preparations for enhanced phase 2b in HCC with fostrox + Lenvima continue
BioStock: Medivir's partner makes clinical progress in veterinary project
Medivir : The Board of Directors statement under Chapter 19 Section 22 of the Swedish Companies Act
Medivir's partner Vetbiolix announces positive results from Proof-of-Concept study with VBX-1000, previously known as MIV-701
BioStock: Medivir continues to accelerate development with fostrox
Medivir : The Nomination Committees proposal for the AGM
Medivir to present at Investing in Oncology Forum on April 10
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción MVIR B
  4. Noticias Medivir AB
  5. Otros idiomas